Neurogene Inc. Lease Obligation Incurred
Neurogene Inc. (NGNE) reported Lease Obligation Incurred of $65.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2019-03-07.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2019-03-07
- Neurogene Inc. lease obligation incurred for the quarter ending 2016-12-31 was $30.00K.
- Neurogene Inc. lease obligation incurred for fiscal 2016 was $65.00K, a 490.91% increase from fiscal 2015.
- Neurogene Inc. lease obligation incurred for fiscal 2015 was $11.00K.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month |
|---|---|---|---|
| 2016-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $65.00K 10-K · filed 2019-03-07 | |
| 2016-09-30 | $35.00K 10-Q · filed 2017-11-08 | ||
| 2015-12-31 | $11.00K 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |